9 patents
Utility
Anti-CD30L antibodies and uses thereof
9 Jan 24
Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).
Jessie-Farah Fecteau, Mark Renshaw, Johan Fransson, Olivier Laurent, Burton Barnett
Filed: 26 Aug 22
Utility
GPR35 modulators
3 Oct 23
Described herein are GPR35 modulators and methods of using these compounds in the treatment of diseases, disorders or conditions.
Robert Higuchi
Filed: 18 May 21
Utility
Optimized anti-TL1A antibodies
13 Sep 22
Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
Filed: 30 Apr 20
Utility
Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
5 Apr 22
Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
Jeffry D. Watkins, Cindy T. Dickerson, Rafael Rojas, Matthew Reissman, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
Filed: 2 Dec 20
Utility
Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A)
5 Oct 21
Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent.
Laurens Kruidenier, Mahyar Sabripour, Janine Bilsborough, Dermot P. McGovern, Dalin Li
Filed: 10 Dec 20
Utility
GPR35 modulators
6 Jul 21
Described herein are GPR35 modulators and methods of using these compounds in the treatment of diseases, disorders or conditions.
Robert Higuchi
Filed: 23 Jan 20
Utility
Assays for detecting neutralizing autoantibodies to biologic therapy
5 Oct 20
The present invention provides assays for detecting and measuring the presence or level of neutralizing and non-neutralizing autoantibodies to biologics such as anti-TNFα drug therapeutics in a sample.
Scott Hauenstein, Linda Ohrmund, Sharat Singh, Shui Long Wang
Filed: 31 Aug 16
Utility
Methods for predicting post-operative recurrence of Crohn's disease
29 Jun 20
The present invention provides methods for predicting post-operative recurrence of Crohn's disease (CD) in a subject.
Steven Lockton, Marc Ferrante, Severine Vermiere, Sharat Singh
Filed: 19 May 16
Utility
Optimized anti-TL1A antibodies
22 Jun 20
Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins
Filed: 24 Nov 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first